Evidence map›Paper›PMID 38093257›Full record

Observational studyJournal of neuroinflammation2023

Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer's disease.

Kaja Nordengen, Bjørn-Eivind Kirsebom, Grit Richter, Lene Pålhaugen, Berglind Gísladóttir, Nikias Siafarikas, Arne Nakling, Arvid Rongve, Geir Bråthen, Gøril Rolfseng Grøntvedt and 12 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Journal of neuroinflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Interpreting p-tau217 on the ward: frailty and plasma biomarkers in acutely admitted older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Repeated plasma p-tau217 measurements to monitor clinical progression heterogeneity.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 14 institutions in 5 countries.

Kaja Nordengen *Department of Neurology, Akershus University Hospital, P.B. 1000, 1478, Lørenskog, Norway. kaja.nordengen@gmail.com.
Bjørn-Eivind Kirsebom *Department of Neurology, University Hospital of North Norway, Tromsø, Norway.
Grit RichterDepartment of Neurology, University Hospital of North Norway, Tromsø, Norway.
Lene PålhaugenDepartment of Neurology, Akershus University Hospital, P.B. 1000, 1478, Lørenskog, Norway.
Berglind GísladóttirDepartment of Neurology, Akershus University Hospital, P.B. 1000, 1478, Lørenskog, Norway.
Nikias SiafarikasDepartment of Old Age Psychiatry, Akershus University Hospital, Lørenskog, Norway.
Arne NaklingInstitute of Clinical Medicine, University of Bergen, Bergen, Norway.
Arvid RongveDepartment of Research and Innovation, Haugesund Hospital, Helse Fonna, Haugesund, Norway.
Geir BråthenDepartment of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Gøril Rolfseng GrøntvedtDepartment of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Fernando GonzalezClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Knut WaterlooDepartment of Neurology, University Hospital of North Norway, Tromsø, Norway.
Kulbhushan SharmaDepartment of Neurology, Akershus University Hospital, P.B. 1000, 1478, Lørenskog, Norway.
Thomas KarikariDepartment of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Eleonora M VromenAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vumc, Amsterdam, the Netherlands.
Betty M TijmsAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vumc, Amsterdam, the Netherlands.
Pieter J VisserAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vumc, Amsterdam, the Netherlands.
Per SelnesDepartment of Neurology, Akershus University Hospital, P.B. 1000, 1478, Lørenskog, Norway.
Milicia G KrambergerDepartment of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Bengt WinbladDepartment of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Stockholm, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Tormod FladbyDepartment of Neurology, Akershus University Hospital, P.B. 1000, 1478, Lørenskog, Norway. tormod.fladby@medisin.uio.no.
Akershus University Hospital · NOUniversity of Oslo · NOAmsterdam University Medical Centers · NLUniversity Hospital of North Norway · NOUniversity of Gothenburg · SEAmsterdam Neuroscience · NLFonna Hospital TrustKarolinska Institutet · SELjubljana University Medical Centre · SINorwegian University of Science and Technology · NOSahlgrenska University Hospital · SESt Olav's University Hospital · NOUiT The Arctic University of Norway · NOUniversity of Bergen · NO

Funding

Plasma brain-derived tau: a novel Alzheimer’s disease-type neurodegeneration biomarker with potential to complete the AT(N) scheme in bloodR01AG083874 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Thomas K Karikari · 2023 to 2026
$14.5M
NIA NIH HHS R01 AG083874
6 · The paper itself

Abstract

backgroundBrain innate immune activation is associated with Alzheimer's disease (AD), but degrees of activation may vary between disease stages. Thus, brain innate immune activation must be assessed in longitudinal clinical studies that include biomarker negative healthy controls and cases with established AD pathology. Here, we employ longitudinally sampled cerebrospinal fluid (CSF) core AD, immune activation and glial biomarkers to investigate early (predementia stage) innate immune activation levels and biomarker profiles.

methodsWe included non-demented cases from a longitudinal observational cohort study, with CSF samples available at baseline (n = 535) and follow-up (n = 213), between 1 and 6 years from baseline (mean 2.8 years). We measured Aβ42/40 ratio, p-tau181, and total-tau to determine Ab (A+), tau-tangle pathology (T+), and neurodegeneration (N+), respectively. We classified individuals into these groups: A-/T-/N-, A+/T-/N-, A+/T+ or N+, or A-/T+ or N+. Using linear and mixed linear regression, we compared levels of CSF sTREM2, YKL-40, clusterin, fractalkine, MCP-1, IL-6, IL-1, IL-18, and IFN-γ both cross-sectionally and longitudinally between groups. A post hoc analysis was also performed to assess biomarker differences between cognitively healthy and impaired individuals in the A+/T+ or N+ group.

resultsCross-sectionally, CSF sTREM2, YKL-40, clusterin and fractalkine were higher only in groups with tau pathology, independent of amyloidosis (p < 0.001, A+/T+ or N+ and A-/T+ or N+, compared to A-/T-/N-). No significant group differences were observed for the cytokines CSF MCP-1, IL-6, IL-10, IL18 or IFN-γ. Longitudinally, CSF YKL-40, fractalkine and IFN-γ were all significantly lower in stable A+/T-/N- cases (all p < 0.05). CSF sTREM2, YKL-40, clusterin, fractalkine (p < 0.001) and MCP-1 (p < 0.05) were all higher in T or N+, with or without amyloidosis at baseline, but remained stable over time. High CSF sTREM2 was associated with preserved cognitive function within the A+/T+ or N+ group, relative to the cognitively impaired with the same A/T/N biomarker profile (p < 0.01).

conclusionsImmune hypoactivation and reduced neuron-microglia communication are observed in isolated amyloidosis while activation and increased fractalkine accompanies tau pathology in predementia AD. Glial hypo- and hyperactivation through the predementia AD continuum suggests altered glial interaction with Ab and tau pathology, and may necessitate differential treatments, depending on the stage and patient-specific activation patterns.

Indexed as

Alzheimer DiseaseAmyloidosisAmyloid beta-PeptidesBiomarkersChemokine CX3CL1Chitinase-3-Like Protein 1ClusterinHumansInterleukin-6tau ProteinsAmyloid beta-PeptidesBiomarkersChemokine CX3CL1Chitinase-3-Like Protein 1ClusterinInterleukin-6tau ProteinsAlzheimer’s diseaseBiomarkersCerebrospinal fluidInflammation

Identifiers

PMID38093257
PMCPMC10720118
OpenAlexW4389686607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.